Guyer Charles Greg 4

What Happened

• Greg Guyer, Executive Vice President and Chief Technical Officer of BioMarin Pharmaceutical Inc. (BMRN), sold 16,486 shares in an open-market transaction on March 11, 2026. The weighted-average sale price was $60.46, producing gross proceeds of approximately $996,744. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: March 11, 2026 (Form 4 filed March 12, 2026 — timely)
• Transaction type: Open-market sale (code S)
• Shares sold: 16,486
• Price: weighted average $60.46; actual sale prices ranged from $60.39 to $60.62 (see footnote)
• Reported proceeds: ~$996,744
• Shares owned after transaction: Not provided in the excerpt supplied
• Footnote: The filing notes the $60.46 figure is a weighted average; the filer can provide the number of shares sold at each specific price upon request
• No 10b5-1 plan, tax-withholding, or option exercise was indicated in the provided information

Context

• This was a straightforward open-market sale. Sales by executives can be routine (for diversification, tax, or liquidity) and do not by themselves indicate company performance. Purchases tend to carry more direct signal for bullish insider sentiment; no purchase or exercise was reported here.